Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world registry of henagliflozin-containing regimens for comprehensive control in adults with type 2 diabetes mellitus
ChiCTR2500098460Phase 4Not yet recruiting
- Sponsor
- Hunan Provincial People's Hospital
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of henagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Hunan Provincial People's Hospital. Primary endpoints: HbA1c at 24 weeks and Body weight at 24 weeks. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
henagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2500098460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500098460.